Introduction
============

Coronary artery disease (CAD) is a major public health challenge globally; CAD is responsible for approximately 32% of deaths worldwide, which exceeds that of all cancers combined in most developed countries ([@ref-12]; [@ref-4]) Depression is a psychological complication that may occur alongside CAD; it is an under-recognized determinant of outcomes in patients with CAD because of its high sudden death rate and poor prognostic association with CAD ([@ref-18]; [@ref-31]). Major depressive disorder and minor depression affect 20% and 30%--45% of patients with CAD, respectively ([@ref-3]).

The direction and cause mechanism of the association between CAD and depression remain unclear. However, many studies have demonstrated their shared risk factors, including hypercortisolemia, inflammation, autonomic arousal, serotonin signaling-altered platelet function, and hypothalamus--pituitary--adrenocortical (HPA) axis dysfunction ([@ref-23]). Genetic factors contribute to the comorbidity of CAD and depression. Genome-wide association study (GWAS), a non-hypothesis-driven and unbiased approach, is a standard tool used to analyze the potential associations between the traits of a disease and single nucleotide polymorphisms (SNPs). Numerous GWASs have been implemented to investigate CAD and depression and involved tens of thousands of case and controls from a great range of geographic, demographic, and ethnic backgrounds. ([@ref-15]; [@ref-27]; [@ref-28]) Over 60 CAD loci were identified for CAD susceptibility ([@ref-25]). According to a GWAS of depression in 2018, 17 variants in excitatory synaptic pathways were identified by a UK Biobank study ([@ref-17]). However, no GWAS of comorbid CAD and depression has been reported. By contrast to GWAS, candidate gene study, which is an approach based on hypothesis, has been applied to uncover the genetic basis of susceptibility to diseases. For example, some gene studies have revealed the association of comorbid CAD and depression with genetic defects in plasminogen activator inhibitor 1, 5-hydroxytryptamine, and apolipoprotein E ([@ref-11]; [@ref-13]; [@ref-21]).

FK506-binding protein (FKBP) is coded by the *FKBP* gene, which is located on chromosome 6. FKBP51 is an important member of the FKBP protein family and is coded by *FKBP5*. FKBP5 is a vital modulator that regulates the amount of biological processes in the periphery and the brain and is a regulator of glucocorticoid receptors (GRs), which are associated with the HPA axis function ([@ref-2]). Glucocorticoids can increase *FKBP5* gene expression in various tissues in a dose-dependent manner ([@ref-22]). GR condition and HPA axis function are closely related to the pathogenesis of CAD and depression ([@ref-6]). Systematic reviews and meta-analysis studies have proven that the SNPs of *FKBP5* are associated with depression ([@ref-26]; [@ref-30]). FKBP5 expression is associated with insulin resistance, type 2 diabetes, and obesity, which are closely related to cardiovascular disease ([@ref-10]; [@ref-33]). The regulation of FKBP5 may be associated with cardiometabolic risk ([@ref-29]; [@ref-35]). Thus, we can reasonably assume that *FKBP5* is associated with CAD susceptibility.

Given its associations with CAD and depression, we speculated that the *FKBP5* gene may be the gene underlying the comorbidity of CAD and depression. This study aimed to investigate the association of *FKBP5* polymorphisms with the susceptibility to comorbid depression in patients with CAD from a Northern Chinese population. Seven SNPs, namely, [rs1360780](http://www.ncbi.nlm.nih.gov/snp/?term=rs1360780) (C\>T), [rs2817032](http://www.ncbi.nlm.nih.gov/snp/?term=rs2817032) (T\>C), [rs2817035](http://www.ncbi.nlm.nih.gov/snp/?term=rs2817035) (G\>A), [rs9296158](http://www.ncbi.nlm.nih.gov/snp/?term=rs9296158) (G\>A), [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079) (G\>A), [rs4713902](http://www.ncbi.nlm.nih.gov/snp/?term=rs4713902) (T\>C), and [rs3800373](http://www.ncbi.nlm.nih.gov/snp/?term=rs3800373) (C\>T), were selected. Their correlation with the comorbidity was evaluated.

Methods
=======

Subjects
--------

This study recruited participants from the First Peoples' Hospital of Jining between February 2016 and May 2018. A total of 270 northern Han Chinese patients with CAD and 113 healthy controls matched with patients' sex and age were enrolled in this study. All patients with CAD were diagnosed by experienced cardiologists on the basis of significant standards: angiographic evidence of luminal diameter narrowing \>50% in at least one main coronary artery, previous history of coronary artery bypass graft surgery, and history of percutaneous coronary intervention. Patients with renal failure, congenital heart disease, tumors, immune system disorders, malignancies, congenital heart disease, and infectious heart disease were excluded. CAD patients with or without depression were assessed by at least two experienced psychiatrists on the basis of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders for depressive disorder, characterized by significant anhedonia and depressed mood. Patient Health Questionnaire-9 (PHQ-9), a commonly used 9-item questionnaire, was used to assess the severity of depressive symptoms. A score that was equal or greater than 5 was used as the cutoff score for depression ([@ref-7]).

Health controls were selected from the physical examination program through clinical examination and electrocardiogram at the same period. This study was designed in accordance with the Declaration of Helsinki and approved by the ethics committee of the First Peoples' Hospital of Jining (approval number: JY2016035). All subjects provided written informed consent.

DNA isolation and genotyping
----------------------------

About 1 ml of peripheral blood was collected and extracted from the subjects using a TIANamp Blood DNA Kit (TIANGEN, China) according to the manufacturer's instructions. The concentration and purity of DNA samples were detected with NanoDrop-1000 (NanoDrop, USA) to ensure that the samples were available for subsequent experiments. All DNA samples were genotyped through polymerase chain reaction (PCR)--ligase detection reaction. PCR of the four target single-nucleotide polymorphisms was amplified by the primers listed in [Table 1](#table-1){ref-type="table"} from each participant. The samples were processed by shrimp alkaline phosphatase, extended, and purified using iPLEX extension reagents (Agena Bioscience, USA) and Nanodispenser RS1000. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry was conducted to detect the primer extension products, and Spectro-Typer was used to automatically analyze the genotyping data. More than 10% of the samples were randomly selected and retested to verify the validity of MassARRAY results.
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###### Primers of FKBP5 genes used in the PCR.
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  SNP                                                            Ancestor allele   Primer sequence                                                               Product size
  -------------------------------------------------------------- ----------------- ----------------------------------------------------------------------------- --------------
  [rs1360780](http://www.ncbi.nlm.nih.gov/snp/?term=rs1360780)   C                 5′-ACGTTGGATGTGCCAGCAGTAGCAAGTAAG-3′ 5′-ACGTTGGATGCAGGCACAGAAGGCTTTCAC-3′     88
  [rs2817032](http://www.ncbi.nlm.nih.gov/snp/?term=rs2817032)   T                 5′- ACGTTGGATGTTTCACAGGTACCCCATTCC-3′ 5′-ACGTTGGATGAATATCACAGGCTTGCTGGG-3′    103
  [rs2817035](http://www.ncbi.nlm.nih.gov/snp/?term=rs2817035)   G                 5′-ACGTTGGATGGTTGCAAACAGAGGTAGGAG-3′ 5′- ACGTTGGATGCTCTTTTCTCCTAGGATCCC-3′    99
  [rs9296158](http://www.ncbi.nlm.nih.gov/snp/?term=rs9296158)   G                 5′- ACGTTGGATGGACCTGGTAATATCACTCTC-3′ 5′- ACGTTGGATGCTGGGCTAGGGGTAATTCAA-3′   118
  [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079)   G                 5′- ACGTTGGATGGCCTCCCAAAATGCTATATC-3′ 5′-ACGTTGGATGATACCATACTCTAGGCTGGG-3′    104
  [rs4713902](http://www.ncbi.nlm.nih.gov/snp/?term=rs4713902)   T                 5′-ACGTTGGATGGGAGCCAAAACATGAAGAGC-3′ 5′-ACGTTGGATGTAGGCAACCTGTATAAGCTG-3′     99
  [rs3800373](http://www.ncbi.nlm.nih.gov/snp/?term=rs3800373)   C                 5′-ACGTTGGATGTGACTTTTTAGTACTAAGC-3′ 5′-ACGTTGGATGCCCTAGTGTAGAAGAGCAAC-3′      101

Statistical analysis
--------------------

All genotyping results of the investigated patients and controls were tested for Hardy--Weinberg equilibrium (HWE) by applying the chi-square test (*χ*2 test). Differences in genotypic distributions and allele frequencies in the cases and controls were compared among groups for statistical significance through chi-square statistics (*χ*2 test). The associations between the genotypes and CAD/CAD with comorbid depression were evaluated via the odds ratio (OR), with 95% confidence interval (CI). A two-sided *p* value below 0.05 was considered statistically significant. All statistical analyses were performed with SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA).

Results
=======

[Table 2](#table-2){ref-type="table"} shows the demographic and clinical characteristics of the participants in this study., No significant differences were found between the CAD and the health control groups in term of age, gender, smoking, drinking and body mass index (BMI) (*P* \> 0.05). No significant differences were observed when the CAD cases were subdivided to the CAD with depression (CAD+D) and CAD without depression (CAD-D) groups based on comorbid depression.
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###### Demographic and clinical characteristics of the participants.
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  Variables         CAD (*n* = 270)   Controls (*n* = 113)   *P*-value[^a^](#table-2fn1){ref-type="fn"}   CAD+D (*n* = 123)   *P*-value[^b^](#table-2fn2){ref-type="fn"}   CAD-D (*n* = 147)   *P*-value[^c^](#table-2fn3){ref-type="fn"}
  ----------------- ----------------- ---------------------- -------------------------------------------- ------------------- -------------------------------------------- ------------------- --------------------------------------------
  Age (yrs)         56.2 ± 10.4       52.9 ± 10.2            0.887                                        57.1 ± 10.2         0.977                                        55.5 ± 10.5         0.820
  Gender (M/F, n)   128/142           52/61                  0.804                                        53/70               0.651                                        75/72               0.424
  Smoking (n, %)    88, 32.5          28, 24.8               0.129                                        36, 29.3            0.438                                        52, 35.3            0.067
  Drinking (n, %)   93, 34.4          33, 29.2               0.319                                        35, 28.4            0.899                                        58, 39.4            0.086
  BMI (kg/m^2^)     24.3 ± 3.3        24.0 ± 3.0             0.205                                        24.4 ± 3.6          0.119                                        24.2 ± 2.9          0.983

**Notes.**

CAD versus Controls.

CAD+D versus Controls.

CAD+D versus CAD-D.

CADcoronary heart diseaseCAD+DCHD with depressionCAD-DCAD without depression

The results demonstrated that the seven observed genotype frequencies were in accordance with the HWE (*P* ≥ 0.088). The genotypic distribution and allele frequencies of the seven genetic polymorphisms between the CAD and control groups in all participants, male participants only, and female participants only were compared ([Table 3](#table-3){ref-type="table"} for all participants, [Table 4](#table-4){ref-type="table"} for female participants with significant results and [Table S1](#supp-1){ref-type="supplementary-material"} for all male participants and all female participants). No statistically significant difference was observed between the patients with CAD and controls for the genotypic and allelic distributions of the [rs1360780](http://www.ncbi.nlm.nih.gov/snp/?term=rs1360780) (C\>T), [rs2817032](http://www.ncbi.nlm.nih.gov/snp/?term=rs2817032) (T\>C), [rs2817035](http://www.ncbi.nlm.nih.gov/snp/?term=rs2817035) (G\>A), [rs9296158](http://www.ncbi.nlm.nih.gov/snp/?term=rs9296158) (G\>A) and [rs3800373](http://www.ncbi.nlm.nih.gov/snp/?term=rs3800373) (C\>T) polymorphisms in the investigated group, including all, male or female participants.
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###### Genotypic and allelic distribution of seven FKBP5 genes between all CAD patients (*n* = 270) and Controls (*n* = 113).
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  SNP                                                            Genotype/ allele   Case,(%)     Control,(%)   *P* value[^a^](#table-3fn3){ref-type="fn"} (*χ*^2^)   OR (95% CI)            *P* value[^b^](#table-3fn4){ref-type="fn"}
  -------------------------------------------------------------- ------------------ ------------ ------------- ----------------------------------------------------- ---------------------- --------------------------------------------
  [rs1360780](http://www.ncbi.nlm.nih.gov/snp/?term=rs1360780)   CC                 134 (49.6)   60 (53.1)     0.644 (0.879)                                         1.00                   Referent
                                                                 CT                 121 (44.8)   49 (43.4)                                                           1.106 (0.705--1.735)   0\. 622
                                                                 TT                 15 (5.6)     4 (3.5)                                                             1.679 (0.535--5.272)   0.375
                                                                 CT+TT              136 (50.4)   53 (46.9)     0.536 (0.383)                                         1.149 (0.740--1.784)   0.563
                                                                 C                  389 (72.0)   169 (74.8)    0.437 (0.605)                                         1.00                   Referent
                                                                 T                  151 (28.0)   57 (25.2)                                                           1.151 (0.808--1.640)   0.151
  [rs2817032](http://www.ncbi.nlm.nih.gov/snp/?term=rs2817032)   TT                 142 (52.6)   69 (61.1)     0.253 (2.748)                                         1.00                   Referent
                                                                 TC                 108 (40.0)   39 (34.5)                                                           1.346 (0.845--2.144)   0.211
                                                                 CC                 20 (7.4)     5 (4.4)                                                             1.944 (0.700--5.397)   0.202
                                                                 TC+CC              128 (47.4)   44 (38.9)     0.129 (2.310)                                         1.414 (0.904--2.211)   0.129
                                                                 T                  392 (72.6)   177 (78.3)    0.098 (2.734)                                         1.00                   Referent
                                                                 C                  148 (27.4)   49 (21.7)                                                           1.364 (0.943--1.972)   0.099
  [rs2817035](http://www.ncbi.nlm.nih.gov/snp/?term=rs2817035)   GG                 121 (44.8)   61 (54.0)     0.040 (6.429)[^\*^](#table-3fn2){ref-type="fn"}       1.00                   Referent
                                                                 GA                 138 (51.1)   52 (46.0)                                                           1.338 (0.859--2.084)   0.198
                                                                 AA                 11 (4.1)     0 (0.0)                                                             --                     --
                                                                 GA+AA              149 (55.2)   52 (46.0)     0.101 (2.685)                                         1.445 (0.930--2.245)   0.102
                                                                 G                  380 (70.4)   174 (77.0)    0.062 (3.489)                                         1.00                   Referent
                                                                 A                  160 (29.6)   52 (23.0)                                                           1.409 (0.982--2.021)   0.062
  [rs9296158](http://www.ncbi.nlm.nih.gov/snp/?term=rs9296158)   GG                 112 (41.5)   47 (41.6)     0.994 (0.013)                                         1.00                   Referent
                                                                 GA                 121 (44.8)   51 (45.1)                                                           0.996 (0.621--1.597)   0.985
                                                                 AA                 37 (13.7)    15 (13.3)                                                           1.035 (0.519--2.064)   0.922
                                                                 GA+AA              158 (58.5)   66 (58.4)     0.984 (0.000)                                         1.005 (0.643--1.569)   0.984
                                                                 G                  345 (63.9)   145 (64.2)    0.943 (0.005)                                         1.00                   Referent
                                                                 A                  195 (36.1)   81 (35.8)                                                           1.012 (0.732--1.398)   0.943
  [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079)   GG                 146 (54.1)   42 (37.2)     0.010 (9.121)[^\*^](#table-3fn2){ref-type="fn"}       1.00                   Referent
                                                                 GA                 102 (37.8)   58 (51.3)                                                           0.506 (0.316--0.810)   0.005[^\*^](#table-3fn2){ref-type="fn"}
                                                                 AA                 22 (8.1)     13 (11.5)                                                           0.487 (0.226--1.048)   0.066
                                                                 GA+AA              124 (45.9)   71 (62.8)     0.003 (9.110)[^\*^](#table-3fn2){ref-type="fn"}       0.502 (0.320--0.788)   0.003[^\*^](#table-3fn2){ref-type="fn"}
                                                                 G                  394 (73.0)   142 (62.8)    0.005 (7.783)[^\*^](#table-3fn2){ref-type="fn"}       1.00                   Referent
                                                                 A                  146 (27.0)   84 (37.2)                                                           0.626 (0.450--0.871)   0.005[^\*^](#table-3fn2){ref-type="fn"}
  [rs4713902](http://www.ncbi.nlm.nih.gov/snp/?term=rs4713902)   TT                 145 (53.7)   73 (64.6)     0.114 (4.351)                                         1.00                   Referent
                                                                 TC                 109 (40.4)   33 (29.2)                                                           1.663 (1.029--2.688)   0.038
                                                                 CC                 16 (5.9)     7 (6.2)                                                             1.151 (0.435--2.921)   0.768
                                                                 TC+CC              125 (46.3)   40 (35.4)     0.049 (3.858)[^\*^](#table-3fn2){ref-type="fn"}       1.573 (0.999--2.477)   0.050[^\*^](#table-3fn2){ref-type="fn"}
                                                                 T                  399 (73.9)   179 (79.2)    0.119 (2.430)                                         1.00                   Referent
                                                                 C                  141 (26.1)   47 (20.8)                                                           1.346 (0.999--2.477)   0.120
  [rs3800373](http://www.ncbi.nlm.nih.gov/snp/?term=rs3800373)   CC                 72 (26.7)    36 (31.9)     0.422 (1.724)                                         1.00                   Referent
                                                                 CA                 182 (67.4)   73 (64.6)                                                           2.000 (0.623--6.421)   0.244
                                                                 AA                 16 (5.9)     4 (3.5)                                                             1.247 (0.769--2.022)   0.372
                                                                 CA+AA              198 (73.3)   77 (68.1)     0.980 (0.001)                                         0.994 (0.607--1.625)   0.980
                                                                 C                  326 (60.4)   145 (64.2)    0.326 (0.966)                                         1.00                   Referent
                                                                 A                  214 (39.6)   81 (35.8)                                                           1.175 (0.852--1.621)   0.326

**Notes.**

AbbreviationsCIconfidence intervalORodds ratio

*P* \< 0.05.

*P* value for genotype and allelefrequencies in cases and controls using 2-sided *χ*^2^ test.

*P* values adjusted by age and genderusing logistic regression.
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###### Genotypic and allelic distribution of FKBP5 ([rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079)) genes between female CAD patients (*n* = 142) and Controls (*n* = 61).
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  SNP                                                            Genotype/ allele   Case,(%)     Control,(%)   *P* value[^a^](#table-4fn3){ref-type="fn"} (*χ*^2^)   OR (95% CI)            *P* value[^b^](#table-4fn4){ref-type="fn"}
  -------------------------------------------------------------- ------------------ ------------ ------------- ----------------------------------------------------- ---------------------- --------------------------------------------
  [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079)   GG                 85 (59.9)    23 (37.7)     0.014 (8.540)[^\*^](#table-4fn2){ref-type="fn"}       1.00                   Referent
                                                                 GA                 58 (40.8)    31 (50.8)                                                           0.419 (0.220--0.799)   0.008[^\*^](#table-4fn2){ref-type="fn"}
                                                                 AA                 9 (6.3)      7 (11.5)                                                            0.348 (0.117--1.035)   0.058
                                                                 GA+AA              57 (47.1)    38 (62.3)     0.004 (8.412)[^\*^](#table-4fn2){ref-type="fn"}       0.406 (0.219--0.752)   0.004[^\*^](#table-4fn2){ref-type="fn"}
                                                                 G                  210 (73.9)   77 (63.1)     0.009 (6.804)[^\*^](#table-4fn2){ref-type="fn"}       1.00                   Referent
                                                                 A                  66 (26.1)    45 (36.9)                                                           0.545 (0.344--0.862)   0.010[^\*^](#table-4fn2){ref-type="fn"}

**Notes.**

AbbreviationsCIconfidence intervalORodds ratio

*P* \< 0.05.

*P* value for genotype and allelefrequencies in cases and controls using 2-sided *χ*^2^ test.

*P* values adjusted by age and genderusing logistic regression.

The TC+CC genotype frequency for [rs4713902](http://www.ncbi.nlm.nih.gov/snp/?term=rs4713902) was significantly higher in the CAD cases than in the controls (*P* = 0.049). For [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079), the GA and GA+AA genotypes were associated with significantly decreased risks of CAD (OR = 0.506, 95% CI \[0.316--0.810\], *p* = 0.005 and OR = 0.502, 95% CI \[0.320--0.788\], *p* = 0.003 for GA and GA+AA, respectively) when the GG genotype was used as the reference The A allele showed a significant association with the CAD group (OR = 0.626, 95% CI \[0.450--0.871\], *p* = 0.005).

Interestingly, no statistically significant difference was found in males in terms of the [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079) genotype and allele frequency, whereas a statistically significant difference was observed among females (OR = 0.419, 95% CI \[0.220--0.799\], *p* = 0.008 for GA vs. GG; OR = 0.406, 95% CI \[0.219--0.752\], *p* = 0.004 for GA+AA vs. GG; OR = 0.545, 95% CI \[0.344--0.862\], *p* = 0.010 for A vs. G).

The patients with CAD were divided into the CAD+D and CAD-D groups based on comorbid depression, and all the investigated genotype and allele frequency distributions of polymorphisms were compared within the CAD+D, CAD-D, and healthy groups. The genotype frequencies of the subgroups were compared with those of the controls, and the results are presented in [Table 5](#table-5){ref-type="table"}, No significant associations were observed in [rs1360780](http://www.ncbi.nlm.nih.gov/snp/?term=rs1360780) (C\>T), [rs2817032](http://www.ncbi.nlm.nih.gov/snp/?term=rs2817032) (T\>C), [rs2817035](http://www.ncbi.nlm.nih.gov/snp/?term=rs2817035) (G\>A) and [rs3800373](http://www.ncbi.nlm.nih.gov/snp/?term=rs3800373) (C\>T) SNPs and CAD of the subgroups (*P* \> 0.05). A significant difference in the genotype and allele frequencies of [rs2817035](http://www.ncbi.nlm.nih.gov/snp/?term=rs2817035) and [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079) was noted in the CAD+H groups compared with the control subjects (*P* \< 0.05 for both comparisons). A significant difference was found in the allele frequency of the [rs4713902](http://www.ncbi.nlm.nih.gov/snp/?term=rs4713902) polymorphism in the CAD+H groups compared with the control subjects (*P* = 0.034).
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###### Genotypic and allele Distribution of seven FKBP polymorphisms among the CAD with depression group, CAD without depression group and control group.
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                                                                 SNP   1            2            3            *P*-value                                             
  -------------------------------------------------------------- ----- ------------ ------------ ------------ ----------- ----------------------------------------- -------
  [rs1360780](http://www.ncbi.nlm.nih.gov/snp/?term=rs1360780)   CC    60 (48.8)    74 (50.3)    60 (53.1)    0.968       0.650                                     0.739
                                                                 CT    56 (45.5)    65 (44.2)    49 (43.4)                                                          
                                                                 TT    7 (5.7)      8 (5.5)      4 (3.5)                                                            
                                                                 C     176 (48.8)   213 (48.8)   169 (48.8)   0.816       0.429                                     0.551
                                                                 T     70 (48.8)    81 (48.8)    57 (48.8)                                                          
  [rs2817032](http://www.ncbi.nlm.nih.gov/snp/?term=rs2817032)   TT    63 (51.2)    79 (53.7)    69 (61.1)    0.733       0.301                                     0.334
                                                                 TC    52 (42.3)    56 (38.1)    39 (34.5)                                                          
                                                                 CC    8 (6.5)      12 (8.2)     5 (4.4)                                                            
                                                                 T     178 (48.8)   214 (48.8)   177 (48.8)   0.991       0.134                                     0.148
                                                                 C     68 (48.8)    80 (48.8)    49 (48.8)                                                          
  [rs2817035](http://www.ncbi.nlm.nih.gov/snp/?term=rs2817035)   GG    52 (42.3)    67 (45.6)    61 (54.0)    0.665       0.021[^\*^](#table-5fn4){ref-type="fn"}   0.098
                                                                 GA    65 (52.8)    75 (51.0)    52 (46.0)                                                          
                                                                 AA    6 (4.9)      5 (3.4)      0 (0.0)                                                            
                                                                 G     169 (48.8)   209 (48.8)   174 (48.8)   0.546       0.043[^\*^](#table-5fn4){ref-type="fn"}   0.130
                                                                 A     77 (48.8)    85 (48.8)    52 (48.8)                                                          
  [rs9296158](http://www.ncbi.nlm.nih.gov/snp/?term=rs9296158)   GG    53 (43.1)    59 (40.1)    47 (41.6)    0.590       0.903                                     0.865
                                                                 GA    56 (45.5)    65 (44.2)    51 (45.1)                                                          
                                                                 AA    14 (11.4)    23 (15.7)    15 (13.3)                                                          
                                                                 G     162 (48.8)   183 (48.8)   145 (48.8)   0.385       0.700                                     0.654
                                                                 A     84 (48.8)    111 (48.8)   81 (48.8)                                                          
  [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079)   GG    71 (57.7)    75 (51.0)    42 (37.2)    0.462       0.006[^\*^](#table-5fn4){ref-type="fn"}   0.083
                                                                 GA    44 (35.8)    58 (39.5)    58 (51.3)                                                          
                                                                 AA    8 (6.5)      14 (9.5)     13 (11.5)                                                          
                                                                 G     186 (48.8)   208 (48.8)   142 (48.8)   0.205       0.003[^\*^](#table-5fn4){ref-type="fn"}   0.056
                                                                 A     60 (48.8)    86 (48.8)    84 (48.8)                                                          
  [rs4713902](http://www.ncbi.nlm.nih.gov/snp/?term=rs4713902)   TT    62 (50.4)    83 (56.5)    73 (64.6)    0.140       0.088                                     0.139
                                                                 TC    50 (40.7)    59 (40.1)    33 (29.2)                                                          
                                                                 CC    11 (8.9)     5 (3.4)      7 (6.2)                                                            
                                                                 T     174 (48.8)   225 (48.8)   179 (48.8)   0.127       0.034[^\*^](#table-5fn4){ref-type="fn"}   0.468
                                                                 C     72 (48.8)    69 (48.8)    47 (48.8)                                                          
  [rs3800373](http://www.ncbi.nlm.nih.gov/snp/?term=rs3800373)   CC    35 (28.5)    37 (25.2)    36 (31.9)    0.702       0.773                                     0.302
                                                                 CA    82 (66.7)    100 (68.0)   73 (64.6)                                                          
                                                                 AA    6 (4.8)      10 (6.8)     4 (3.5)                                                            
                                                                 C     152 (48.8)   174 (48.8)   145 (48.8)   0.538       0.594                                     0.248
                                                                 A     94 (48.8)    120 (48.8)   81 (48.8)                                                          

**Notes.**

AbbreviationsCIconfidence intervalORodds ratioCAD+DCAD with depressionCAD-DCAD without depression

*P* value for genotype and allele frequencies in cases and controls using 2-sided *χ*^2^ test.

*P* values adjusted by age and gender using logistic regression.

*P* \< 0.05.

Stratification comparison by gender was performed for genotype and allele frequencies of [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079) in the CAD+D, CAD-D and healthy groups. The results present in [Table 6](#table-6){ref-type="table"}. The combination of the [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079) polymorphism was not associated with CAD comorbid depression or not in male group. However, significant differences were observed in the genotype frequency of [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079) in both CAD+D and CAD-D groups compared with the female control group (*P* = 0.039 and *P* = 0.036, respectively). Allele frequency of the [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079) polymorphism was significantly different in the CAD+D and CAD-D groups compared with the female control group (*P* = 0.019 and *P* = 0.013, respectively).
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###### Genotypic and Allelic Distribution of FKBP5 ([rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079)) polymorphisms among the three studied groups between different genders.

![](peerj-08-9286-g006)

            SNP   1            2            3           *P*-value                                             
  --------- ----- ------------ ------------ ----------- ----------- ----------------------------------------- -----------------------------------------
  Males           *n* = 53     *n* = 75     *n* = 52                                                          
            GG    29 (54.7)    32 (42.7)    19 (36.5)   0.236       0.148                                     0.679
            GA    21 (39.6)    33 (44.0)    27 (52.0)                                                         
            AA    3 (5.7)      10 (13.3)    6 (11.5)                                                          
            G     79 (74.5)    97 (64.7)    65 (62.5)   0.094       0.060                                     0.724
            A     27 (25.5)    53 (35.3)    39 (37.5)                                                         
  Females         *n* = 70     *n* = 72     *n* = 61                                                          
            GG    42 (60.0)    43 (59.7)    23 (37.7)   0.975       0.039[^\*^](#table-6fn2){ref-type="fn"}   0.036[^\*^](#table-6fn2){ref-type="fn"}
            GA    23 (32.9)    25 (34.7)    31 (50.8)                                                         
            AA    5 (7.1)      4 (5.6)      7 (11.5)                                                          
            G     107 (76.4)   111 (77.1)   77 (63.1)   0.896       0.019[^\*^](#table-6fn2){ref-type="fn"}   0.013[^\*^](#table-6fn2){ref-type="fn"}
            A     33 (23.6)    33 (22.9)    45 (36.9)                                                         

**Notes.**

CAD+DCAD with depressionCAD-DCAD without depression

*P* \< 0.05.

Discussion
==========

FKBP51 is a FK506-binding protein with high molecular weight and is coded by the *FKBP5* gene, which consists of 13 exons located on chromosome 6 (6p21.31). FKBP51 has important roles in the pathogenesis of psychological complications, such as depression, obsessive--compulsive disorder, and schizophrenia ([@ref-5]; [@ref-9]). FKBP51 affects GR activity by reducing its binding affinity and regulating the HPA axis. FKBP51 can inhibit other steroid hormone receptors, including progesterone and androgen receptors ([@ref-19]). The conditions of GRs, HPA axis, and steroid hormone receptors are related to the pathogenesis of CAD. Some studies reported an association between the *FKBP5* gene and cardiovascular risk.

GWAS is a powerful way to identify the genes involved in human disease, but this approach has not detected the effects of the FKBP5 locus ([@ref-16]). However, FKBP5 gene variations have been associated with risks for varying disorders. Thus, we investigated the association of *FKBP5* gene polymorphisms with the susceptibility of patients with CAD in a northern Chinese population. The GA and GA+AA genotypes of [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079) were associated with a remarkably decreased risk of CAD. The exact mechanism underlying the effect of FKBP5 on CAD is unclear, but some reports have provided evidence of the processes involved. The epigenetic upregulation of FKBP5 caused by aging and stress is driven by FKBP5--nuclear factor kappa-light-chain-enhancer of activated B cell signaling, mediates inflammation, and contributes to cardiovascular risk ([@ref-35]). [@ref-29] stated that cardiometabolic risk may be associated with increased DNA methylation of *FKBP5*, which is associated with the risk factors for CAD, such as the higher levels of glycosylated hemoglobin, low-density lipoprotein cholesterol, body mass index, and waist circumference. Moreover, FKBP5 increases platelet expression in patients with myocardial infarction, which mostly occurs because of CAD ([@ref-8]).

We further classified the CAD group into CAD+D and CAD-D groups depending on the presence of comorbid depression to investigate the association of *FKBP5* gene polymorphism with susceptibility to CAD with comorbid depression. The genotypes and alleles of [rs2817035](http://www.ncbi.nlm.nih.gov/snp/?term=rs2817035) and [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079) and the alleles of [rs4713902](http://www.ncbi.nlm.nih.gov/snp/?term=rs4713902) showed significant differences only between the CAD+D and control groups but not between the CAD-D and control groups and between CAD+D and CAD-D groups. Rs4713902 polymorphisms interact with chronic low family support in association with a child's mental health status ([@ref-1]). [@ref-9] reported that individuals with [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079)---A show a reduced dexamethasone suppression test ratio and suggested a probable effect between the FKBP5 [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079) polymorphism and impaired HPA axis negative feedback in major depression. However, we did not find any remarkable differences in these FKBP5 polymorphisms for the CAD+D group compared with the CAD-D and healthy control groups. Other studies focused on the effect of FKBP5 SNPs [rs1360780](http://www.ncbi.nlm.nih.gov/snp/?term=rs1360780) and [rs3800373](http://www.ncbi.nlm.nih.gov/snp/?term=rs3800373) on depression. [@ref-26] revealed that [rs1360780](http://www.ncbi.nlm.nih.gov/snp/?term=rs1360780) possibly moderates the effects of systemic lupus erythematous in depression and that [rs3800373](http://www.ncbi.nlm.nih.gov/snp/?term=rs3800373) is associated with a remarkable increased risk of depressive disorders. We failed to demonstrate the association between the CAD+D and CAD-D group or healthy control groups for [rs1360780](http://www.ncbi.nlm.nih.gov/snp/?term=rs1360780) or [rs3800373](http://www.ncbi.nlm.nih.gov/snp/?term=rs3800373). These results suggested that common depression and depression comorbid with CAD may have different pathogenetic mechanisms.

CAD is a sex-dependent disease that is two to five times more common in middle-aged men than in their women counterparts; its incidence has decreased in men but has increased in women ([@ref-32]; [@ref-34]). Our results presented a remarkable association between [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079) and CAD in the female groups but not in the male groups. Depressive disorders are twice as likely to occur in women than in men ([@ref-14]). Thus, we investigated the genotypic and allelic distributions of the [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079) polymorphism in the CAD+D, CAD-D, and control groups between different genders. The results showed a significant difference in the genotypic and allelic distributions of the [rs9470079](http://www.ncbi.nlm.nih.gov/snp/?term=rs9470079) polymorphisms in the CAD+D and CAD-D groups compared with the controls in the female groups but not in the male groups. Thus, genetics may play different roles in different genders. The present results were consistent with those of a previous study on depression and CAD in Swedish twins ([@ref-20]), which demonstrated that genetic sources play a large role in CAD+D comorbidity in women, whereas environmental effects play a large role in CAD-D in men. The *FKBP5* gene contains hormone response elements that can bind receptors to sex hormones ([@ref-24]). These elements have different levels in males and females and may play a role in the association of CAD with comorbid depression in different genders.

Several limitations of this study had to be mentioned. First, this study only evaluated a small population in northern China, and the sample size was limited. Genetic polymorphisms of ethnic differences may determine varying functions in different populations. Thus, large sample sizes from different groups are required to obtain reliable outcomes. Second, this study only tested seven of the genotypes of *FKBP5* and the tagging of the *FKBP5* gene was incomplete. Thus, this study could not fully reflect the association of the polymorphisms of FKBP5 with comorbid CAD and depression. A previous study spanning the whole *FKBP5* gene showed 18 SNPs in strong linkage disequilibrium among Caucasians ([@ref-36]). However, we did not found linkage disequilibrium in our study (data no shown), probably owing to the limited number of samples or the incomplete gene locus. Third, the data on FKPB51 level were insufficient, and we failed to assess the influence of FKBP5 expression on the incidence of comorbid CAD and depression by regulating the FKPB51 level.

Conclusion
==========

The current study proposed a remarkable association between *FKBP5* gene variations and the risk of comorbid CAD and depression in a Northern Chinese population. Rs9470079 may be a potential gene locus for the incidence of comorbid CAD and depression. The present findings should be verified through replication studies on large ethnically disparate specimens and with variants covering the whole gene. The exact role of *FKBP5* gene polymorphisms in the pathogenesis of comorbid CAD and depression requires further investigation.
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